These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26129810)

  • 1. A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.
    Campbell JR; Sasitharan T; Marra F
    Appl Health Econ Health Policy; 2015 Aug; 13(4):325-40. PubMed ID: 26129810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
    Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
    JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups.
    Auguste P; Tsertsvadze A; Court R; Pink J
    Tuberculosis (Edinb); 2016 Jul; 99():81-91. PubMed ID: 27450009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priorities for screening and treatment of latent tuberculosis infection in the United States.
    Linas BP; Wong AY; Freedberg KA; Horsburgh CR
    Am J Respir Crit Care Med; 2011 Sep; 184(5):590-601. PubMed ID: 21562129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of diagnosis and treatment for latent tuberculosis infection among contacts of pulmonary tuberculosis patients in Thailand.
    Yoopetch P; Wu O; Jittikoon J; Thavorncharoensap M; Youngkong S; Praditsitthikorn N; Mahasirimongkol S; Anothaisintawee T; Udomsinprasert W; Chaikledkaew U
    Sci Rep; 2024 Jul; 14(1):17693. PubMed ID: 39085338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants.
    Campbell JR; Krot J; Elwood K; Cook V; Marra F
    Mol Diagn Ther; 2015 Feb; 19(1):9-24. PubMed ID: 25579159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis.
    Haukaas FS; Arnesen TM; Winje BA; Aas E
    Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children.
    Laskin BL; Goebel J; Starke JR; Schauer DP; Eckman MH
    Am J Kidney Dis; 2013 Jan; 61(1):22-32. PubMed ID: 22784996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal.
    Sousa S; Rocha D; Silva JC; Ribeiro AI; Gonçalves G; Almeida Á; Correia AM; Duarte R; Carvalho C
    Pulmonology; 2021; 27(6):493-499. PubMed ID: 34053903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.
    Campbell JR; Johnston JC; Ronald LA; Sadatsafavi M; Balshaw RF; Cook VJ; Levin A; Marra F
    Am J Kidney Dis; 2019 Jan; 73(1):39-50. PubMed ID: 30269868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis.
    Campbell JR; Winters N; Menzies D
    BMJ; 2020 Mar; 368():m549. PubMed ID: 32156698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries.
    Hardy AB; Varma R; Collyns T; Moffitt SJ; Mullarkey C; Watson JP
    Thorax; 2010 Feb; 65(2):178-80. PubMed ID: 19996345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Screening Strategy for Latent Tuberculosis Infection (LTBI) in Contacts of Tuberculosis Patients: Systematic Review and Quality Assessment.
    Yoopetch P; Chitpim N; Jittikoon J; Udomsinprasert W; Thavorncharoensap M; Youngkong S; Praditsitthikorn N; Mahasirimongkol S; Chaikledkaew U
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI.
    Oxlade O; Pinto M; Trajman A; Menzies D
    PLoS One; 2013; 8(3):e56044. PubMed ID: 23505412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
    Diel R; Lampenius N; Nienhaus A
    Pharmacoeconomics; 2015 Aug; 33(8):783-809. PubMed ID: 25774015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterium Tuberculosis Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube Test Among Immigrants to the U.S.
    Wilson FA; Miller TL; Stimpson JP
    Public Health Rep; 2016; 131(2):303-10. PubMed ID: 26957665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis.
    Pareek M; Watson JP; Ormerod LP; Kon OM; Woltmann G; White PJ; Abubakar I; Lalvani A
    Lancet Infect Dis; 2011 Jun; 11(6):435-44. PubMed ID: 21514236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of cost and cost-effectiveness of different TB-screening strategies.
    Nienhaus A; Schablon A; Costa JT; Diel R
    BMC Health Serv Res; 2011 Sep; 11():247. PubMed ID: 21961888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.
    Mullie GA; Schwartzman K; Zwerling A; N'Diaye DS
    BMC Med; 2017 May; 15(1):104. PubMed ID: 28514962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.